Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 367

1.

Fragment-based discovery of a potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of ERK1/2.

Heightman TD, Berdini V, Braithwaite H, Buck IM, Cassidy M, Castro J, Courtin A, Day JEH, East C, Fazal L, Graham B, Griffiths-Jones CM, Lyons JF, Martins V, Muench S, Munck JM, Norton D, O'Reilly M, Palmer N, Pathuri P, Reader M, Rees DC, Rich SJ, Richardson C, Saini H, Thompson NT, Wallis NG, Walton H, Wilsher NE, Woolford AJ, Cooke M, Cousin D, Onions S, Shannon J, Watts J, Murray CW.

J Med Chem. 2018 May 18. doi: 10.1021/acs.jmedchem.8b00421. [Epub ahead of print]

PMID:
29775310
2.

White matter integrity and processing speed in sickle cell anemia.

Stotesbury H, Kirkham FJ, Kölbel M, Balfour P, Clayden JD, Sahota S, Sakaria S, Saunders DE, Howard J, Kesse-Adu R, Inusa B, Pelidis M, Chakravorty S, Rees DC, Awogbade M, Wilkey O, Layton M, Clark CA, Kawadler JM.

Neurology. 2018 May 11. pii: 10.1212/WNL.0000000000005644. doi: 10.1212/WNL.0000000000005644. [Epub ahead of print]

PMID:
29752305
3.

Organic synthesis provides opportunities to transform drug discovery.

Blakemore DC, Castro L, Churcher I, Rees DC, Thomas AW, Wilson DM, Wood A.

Nat Chem. 2018 Apr;10(4):383-394. doi: 10.1038/s41557-018-0021-z. Epub 2018 Mar 22. Review.

PMID:
29568051
4.

Proteomic analysis of plasma from children with sickle cell anemia and silent cerebral infarction.

Tewari S, Renney G, Brewin J, Gardner K, Kirkham F, Inusa B, Barrett JE, Menzel S, Thein SL, Ward M, Rees DC.

Haematologica. 2018 Mar 15. pii: haematol.2018.187815. doi: 10.3324/haematol.2018.187815. [Epub ahead of print]

5.

The effect of xanthine oxidase and hypoxanthine on the permeability of red cells from patients with sickle cell anemia.

Al Balushi HWM, Rees DC, Brewin JN, Hannemann A, Gibson JS.

Physiol Rep. 2018 Mar;6(5). doi: 10.14814/phy2.13626.

6.

g(HbF): a genetic model of fetal hemoglobin in sickle cell disease.

Gardner K, Fulford T, Silver N, Rooks H, Angelis N, Allman M, Nkya S, Makani J, Howard J, Kesse-Adu R, Rees DC, Stuart-Smith S, Yeghen T, Awogbade M, Sangeda RZ, Mgaya J, Patel H, Newhouse S, Menzel S, Thein SL.

Blood Adv. 2018 Feb 13;2(3):235-239. doi: 10.1182/bloodadvances.2017009811.

7.

How I manage red cell transfusions in patients with sickle cell disease.

Rees DC, Robinson S, Howard J.

Br J Haematol. 2018 Feb;180(4):607-617. doi: 10.1111/bjh.15115. Epub 2018 Jan 29. Review.

PMID:
29377071
8.

Overnight auto-adjusting continuous airway pressure + standard care compared with standard care alone in the prevention of morbidity in sickle cell disease phase II (POMS2b): study protocol for a randomised controlled trial.

Howard J, Slee AE, Skene S, Inusa B, Kawadler J, Downes M, Gavlak J, Koelbel M, Stotesbury H, Chorozoglou M, Tebbs S, Chakravorty S, Awogbade M, Rees DC, Gupta A, Murphy PB, Hart N, Sahota S, Nwosu C, Gwam M, Saunders D, Muthurangu V, Barber N, Ako E, Thein SL, Marshall M, Reading IC, Cheng MYE, Kirkham FJ, Liossi C.

Trials. 2018 Jan 22;19(1):55. doi: 10.1186/s13063-017-2419-0.

9.

Are the risks of treatment to cure a child with severe sickle cell disease too high?

de Montalembert M, Brousse V, Chakravorty S, Pagliuca A, Porter J, Telfer P, Vora A, Rees DC.

BMJ. 2017 Nov 23;359:j5250. doi: 10.1136/bmj.j5250. No abstract available.

PMID:
29170154
10.

Fragment-to-Lead Medicinal Chemistry Publications in 2016.

Johnson CN, Erlanson DA, Jahnke W, Mortenson PN, Rees DC.

J Med Chem. 2018 Mar 8;61(5):1774-1784. doi: 10.1021/acs.jmedchem.7b01298. Epub 2017 Oct 31.

PMID:
29087197
11.

Correction to Reversible Protonated Resting State of the Nitrogenase Active Site.

Morrison CN, Spatzal T, Rees DC.

J Am Chem Soc. 2017 Oct 4;139(39):13958. doi: 10.1021/jacs.7b09849. Epub 2017 Sep 26. No abstract available.

12.

The significance of inadequate transcranial Doppler studies in children with sickle cell disease.

Greenwood S, Deane C, Rees OL, Freedman B, Kumar S, Ben Ramadan N, Wilkinson S, Marais G, Lord J, Chakravorty S, Height SE, Gardner K, Rees DC.

PLoS One. 2017 Jul 25;12(7):e0181681. doi: 10.1371/journal.pone.0181681. eCollection 2017.

13.

Sickle Cell Disease.

Piel FB, Steinberg MH, Rees DC.

N Engl J Med. 2017 Jul 20;377(3):305. doi: 10.1056/NEJMc1706325. No abstract available.

PMID:
28723338
14.

Electrochemical and structural characterization of Azotobacter vinelandii flavodoxin II.

Segal HM, Spatzal T, Hill MG, Udit AK, Rees DC.

Protein Sci. 2017 Oct;26(10):1984-1993. doi: 10.1002/pro.3236. Epub 2017 Aug 30.

15.

The super sickling haemoglobin HbS-Oman: a study of red cell sickling, K+ permeability and associations with disease severity in patients heterozygous for HbA and HbS-Oman (HbA/S-Oman genotype).

Al Balushi HWM, Wali Y, Al Awadi M, Al-Subhi T, Rees DC, Brewin JN, Hannemann A, Gibson JS.

Br J Haematol. 2017 Oct;179(2):256-265. doi: 10.1111/bjh.14851. Epub 2017 Jul 12.

PMID:
28699687
16.

Reversible Protonated Resting State of the Nitrogenase Active Site.

Morrison CN, Spatzal T, Rees DC.

J Am Chem Soc. 2017 Aug 9;139(31):10856-10862. doi: 10.1021/jacs.7b05695. Epub 2017 Jul 26. Erratum in: J Am Chem Soc. 2017 Oct 4;139(39):13958.

17.

Prasugrel hydrochloride for the treatment of sickle cell disease.

Conran N, Rees DC.

Expert Opin Investig Drugs. 2017 Jul;26(7):865-872. doi: 10.1080/13543784.2017.1335710. Epub 2017 Jun 12. Review.

PMID:
28562105
18.

Recommendations regarding splenectomy in hereditary hemolytic anemias.

Iolascon A, Andolfo I, Barcellini W, Corcione F, Garçon L, De Franceschi L, Pignata C, Graziadei G, Pospisilova D, Rees DC, de Montalembert M, Rivella S, Gambale A, Russo R, Ribeiro L, Vives-Corrons J, Martinez PA, Kattamis A, Gulbis B, Cappellini MD, Roberts I, Tamary H; Working Study Group on Red Cells and Iron of the EHA.

Haematologica. 2017 Aug;102(8):1304-1313. doi: 10.3324/haematol.2016.161166. Epub 2017 May 26.

19.

Sickle Cell Disease.

Piel FB, Steinberg MH, Rees DC.

N Engl J Med. 2017 Apr 20;376(16):1561-1573. doi: 10.1056/NEJMra1510865. Review. No abstract available.

20.

Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor.

Perera TPS, Jovcheva E, Mevellec L, Vialard J, De Lange D, Verhulst T, Paulussen C, Van De Ven K, King P, Freyne E, Rees DC, Squires M, Saxty G, Page M, Murray CW, Gilissen R, Ward G, Thompson NT, Newell DR, Cheng N, Xie L, Yang J, Platero SJ, Karkera JD, Moy C, Angibaud P, Laquerre S, Lorenzi MV.

Mol Cancer Ther. 2017 Jun;16(6):1010-1020. doi: 10.1158/1535-7163.MCT-16-0589. Epub 2017 Mar 24.

PMID:
28341788
21.

An Audit of the Use of Gonadorelin Analogues to Prevent Recurrent Acute Symptoms in Patients with Acute Porphyria in the United Kingdom.

Schulenburg-Brand D, Gardiner T, Guppy S, Rees DC, Stein P, Barth J, Felicity Stewart M, Badminton M.

JIMD Rep. 2017;36:99-107. doi: 10.1007/8904_2017_2. Epub 2017 Feb 21.

22.

Update review of the acute porphyrias.

Stein PE, Badminton MN, Rees DC.

Br J Haematol. 2017 Feb;176(4):527-538. doi: 10.1111/bjh.14459. Epub 2016 Dec 16. Review.

PMID:
27982422
23.

Real-time dose adjustment using point-of-care platelet reactivity testing in a double-blind study of prasugrel in children with sickle cell anaemia.

Jakubowski JA, Hoppe CC, Zhou C, Smith BE, Brown PB, Heath LE, Inusa B, Rees DC, Small DS, Gupta N, Yao S, Heeney M, Kanter J.

Thromb Haemost. 2017 Feb 28;117(3):580-588. doi: 10.1160/TH16-09-0731. Epub 2016 Dec 8.

PMID:
27929203
24.

Associations between environmental factors and hospital admissions for sickle cell disease.

Piel FB, Tewari S, Brousse V, Analitis A, Font A, Menzel S, Chakravorty S, Thein SL, Inusa B, Telfer P, de Montalembert M, Fuller GW, Katsouyanni K, Rees DC.

Haematologica. 2017 Apr;102(4):666-675. doi: 10.3324/haematol.2016.154245. Epub 2016 Dec 1.

25.

Sickle cell disease: Status with particular reference to India.

Rees DC, Brousse VA.

Indian J Med Res. 2016 Jun;143(6):675-677. doi: 10.4103/0971-5916.191916. No abstract available.

26.

Fragment-to-Lead Medicinal Chemistry Publications in 2015.

Johnson CN, Erlanson DA, Murray CW, Rees DC.

J Med Chem. 2017 Jan 12;60(1):89-99. doi: 10.1021/acs.jmedchem.6b01123. Epub 2016 Oct 14. Review.

PMID:
27739691
27.

Nocturnal enuresis and K+ transport in red blood cells from patients with sickle cell anemia.

Tewari S, Rees DC, Hannemann A, Gbotosho OT, Al Balushi HW, Gibson JS.

Haematologica. 2016 Dec;101(12):e469-e472. Epub 2016 Sep 1. No abstract available.

28.

How benign is sickle cell trait?

Gibson JS, Rees DC.

EBioMedicine. 2016 Sep;11:21-22. doi: 10.1016/j.ebiom.2016.08.023. Epub 2016 Aug 21. No abstract available.

29.

Extracranial internal carotid artery stenosis in children with sickle cell disease - Which transducer, what measurement?

Deane CR, Freedman BJ, Height SE, Rees DC.

Ultrasound. 2016 May;24(2):86-93. doi: 10.1177/1742271X16638891. Epub 2016 Mar 16.

30.

Prasugrel for Sickle Cell Vaso-Occlusive Events.

Heeney MM, Hoppe CC, Rees DC.

N Engl J Med. 2016 Jul 14;375(2):185-6. doi: 10.1056/NEJMc1603499. No abstract available.

31.

Haemoglobinopathies and the rheumatologist.

Hughes M, Akram Q, Rees DC, Jones AK.

Rheumatology (Oxford). 2016 Dec;55(12):2109-2118. Epub 2016 Mar 27. Review.

PMID:
27018056
32.

Nitrogenase FeMoco investigated by spatially resolved anomalous dispersion refinement.

Spatzal T, Schlesier J, Burger EM, Sippel D, Zhang L, Andrade SL, Rees DC, Einsle O.

Nat Commun. 2016 Mar 14;7:10902. doi: 10.1038/ncomms10902.

33.

Cation Homeostasis in Red Cells From Patients With Sickle Cell Disease Heterologous for HbS and HbC (HbSC Genotype).

Hannemann A, Rees DC, Tewari S, Gibson JS.

EBioMedicine. 2015 Sep 18;2(11):1669-76. doi: 10.1016/j.ebiom.2015.09.026. eCollection 2015 Nov.

34.

Design and synthesis of dihydroisoquinolones for fragment-based drug discovery (FBDD).

Palmer N, Peakman TM, Norton D, Rees DC.

Org Biomol Chem. 2016 Feb 7;14(5):1599-610. doi: 10.1039/c5ob02461g.

PMID:
26741115
35.

Catalysis-dependent selenium incorporation and migration in the nitrogenase active site iron-molybdenum cofactor.

Spatzal T, Perez KA, Howard JB, Rees DC.

Elife. 2015 Dec 16;4:e11620. doi: 10.7554/eLife.11620.

36.

A Multinational Trial of Prasugrel for Sickle Cell Vaso-Occlusive Events.

Heeney MM, Hoppe CC, Abboud MR, Inusa B, Kanter J, Ogutu B, Brown PB, Heath LE, Jakubowski JA, Zhou C, Zamoryakhin D, Agbenyega T, Colombatti R, Hassab HM, Nduba VN, Oyieko JN, Robitaille N, Segbefia CI, Rees DC; DOVE Investigators.

N Engl J Med. 2016 Feb 18;374(7):625-35. doi: 10.1056/NEJMoa1512021. Epub 2015 Dec 8.

37.

Opportunity Knocks: Organic Chemistry for Fragment-Based Drug Discovery (FBDD).

Murray CW, Rees DC.

Angew Chem Int Ed Engl. 2016 Jan 11;55(2):488-92. doi: 10.1002/anie.201506783. Epub 2015 Nov 3. No abstract available.

PMID:
26526786
38.
39.

Environmental determinants of severity in sickle cell disease.

Tewari S, Brousse V, Piel FB, Menzel S, Rees DC.

Haematologica. 2015 Sep;100(9):1108-16. doi: 10.3324/haematol.2014.120030. Review.

40.

Novel mutations in PIEZO1 cause an autosomal recessive generalized lymphatic dysplasia with non-immune hydrops fetalis.

Fotiou E, Martin-Almedina S, Simpson MA, Lin S, Gordon K, Brice G, Atton G, Jeffery I, Rees DC, Mignot C, Vogt J, Homfray T, Snyder MP, Rockson SG, Jeffery S, Mortimer PS, Mansour S, Ostergaard P.

Nat Commun. 2015 Sep 3;6:8085. doi: 10.1038/ncomms9085.

41.

Prevention of Morbidity in sickle cell disease--qualitative outcomes, pain and quality of life in a randomised cross-over pilot trial of overnight supplementary oxygen and auto-adjusting continuous positive airways pressure (POMS2a): study protocol for a randomised controlled trial.

Howard J, Inusa B, Liossi C, Jacob E, Murphy PB, Hart N, Gavlak J, Sahota S, Chorozoglou M, Nwosu C, Gwam M, Gupta A, Rees DC, Thein SL, Reading IC, Kirkham FJ, Cheng MY.

Trials. 2015 Aug 25;16:376. doi: 10.1186/s13063-015-0883-y.

42.

Fragment-Based Drug Discovery Targeting Inhibitor of Apoptosis Proteins: Discovery of a Non-Alanine Lead Series with Dual Activity Against cIAP1 and XIAP.

Chessari G, Buck IM, Day JE, Day PJ, Iqbal A, Johnson CN, Lewis EJ, Martins V, Miller D, Reader M, Rees DC, Rich SJ, Tamanini E, Vitorino M, Ward GA, Williams PA, Williams G, Wilsher NE, Woolford AJ.

J Med Chem. 2015 Aug 27;58(16):6574-88. doi: 10.1021/acs.jmedchem.5b00706. Epub 2015 Aug 7.

PMID:
26218264
43.

The Effect of Detergent, Temperature, and Lipid on the Oligomeric State of MscL Constructs: Insights from Mass Spectrometry.

Reading E, Walton TA, Liko I, Marty MT, Laganowsky A, Rees DC, Robinson CV.

Chem Biol. 2015 May 21;22(5):593-603. doi: 10.1016/j.chembiol.2015.04.016.

44.

A sulfur-based transport pathway in Cu+-ATPases.

Mattle D, Zhang L, Sitsel O, Pedersen LT, Moncelli MR, Tadini-Buoninsegni F, Gourdon P, Rees DC, Nissen P, Meloni G.

EMBO Rep. 2015 Jun;16(6):728-40. doi: 10.15252/embr.201439927. Epub 2015 May 8.

45.

Powering Brain Power: GLUT1 and the Era of Structure Based Human Transporter Biology.

Rees DC.

Natl Sci Rev. 2015 Mar;2(1):3-4. No abstract available.

46.

13-valent pneumococcal conjugate vaccine (PCV13) is immunogenic and safe in children 6-17 years of age with sickle cell disease previously vaccinated with 23-valent pneumococcal polysaccharide vaccine (PPSV23): Results of a phase 3 study.

De Montalembert M, Abboud MR, Fiquet A, Inati A, Lebensburger JD, Kaddah N, Mokhtar G, Piga A, Halasa N, Inusa B, Rees DC, Heath PT, Telfer P, Driscoll C, Al Hajjar S, Tozzi A, Jiang Q, Emini EA, Gruber WC, Gurtman A, Scott DA.

Pediatr Blood Cancer. 2015 Aug;62(8):1427-36. doi: 10.1002/pbc.25502. Epub 2015 Mar 23.

PMID:
25810327
47.

The contribution of methionine to the stability of the Escherichia coli MetNIQ ABC transporter-substrate binding protein complex.

Nguyen PT, Li QW, Kadaba NS, Lai JY, Yang JG, Rees DC.

Biol Chem. 2015 Sep;396(9-10):1127-34. doi: 10.1515/hsz-2015-0131.

48.

Audit of the Use of Regular Haem Arginate Infusions in Patients with Acute Porphyria to Prevent Recurrent Symptoms.

Marsden JT, Guppy S, Stein P, Cox TM, Badminton M, Gardiner T, Barth JH, Stewart MF, Rees DC.

JIMD Rep. 2015;22:57-65. doi: 10.1007/8904_2015_411. Epub 2015 Mar 12.

49.

The clinical significance of K-Cl cotransport activity in red cells of patients with HbSC disease.

Rees DC, Thein SL, Osei A, Drasar E, Tewari S, Hannemann A, Gibson JS.

Haematologica. 2015 May;100(5):595-600. doi: 10.3324/haematol.2014.120402. Epub 2015 Mar 6.

50.

Substrate pathways in the nitrogenase MoFe protein by experimental identification of small molecule binding sites.

Morrison CN, Hoy JA, Zhang L, Einsle O, Rees DC.

Biochemistry. 2015 Mar 24;54(11):2052-60. doi: 10.1021/bi501313k. Epub 2015 Mar 9.

Supplemental Content

Support Center